Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ABHD10 | Q9NUJ1 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | IL6ST | P40189 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4039245 | 1.00 | P2RX4 (0.32) | P2RX4CYP2D6BCHEABHD10TSHR | |
| SCHEMBL4077659 | 0.81 | CHRM2 (0.44) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL4077655 | 0.81 | CHRM2 (0.44) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL13609108 | 0.81 | CHRM2 (0.44) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL4074592 | 0.80 | ALDH1A1 (0.34) | P2RX4CYP2D6BCHETSHRGPR119 | |
| SCHEMBL4074595 | 0.80 | ALDH1A1 (0.34) | P2RX4CYP2D6BCHETSHRGPR119 | |
| SCHEMBL4074294 | 0.80 | ALDH1A1 (0.34) | P2RX4CYP2D6BCHETSHRGPR119 | |
| SCHEMBL13738462 | 0.79 | MAPK1 (0.41) | GPR119SMN1; SMN2 | |
| SCHEMBL4028667 | 0.79 | PIK3CD (0.32) | TSHRGPR119 | |
| SCHEMBL3941206 | 0.76 | CETP (0.34) | P2RX4CYP2D6BCHEABHD10GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049517-B1 | AMINO-PIPERIDINE DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2013-11-27 | — | — | EP | disclosed |
| US-20090286790-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-11-19 | — | — | US | disclosed |
| EP-2049517-A1 | AMINO-PIPERIDINE DERIVATIVES AS CETP INHIBITORS | Novartis AG (CH) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008009435-A1 | AMINO-PIPERIDINE DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286790-A1 | ORGANIC COMPOUNDS | CETP, NPC1, CES1 | P2RX4 3161/4885CYP2D6 482/4885BCHE 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.